Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 264 participants.

Also called NCT03437226

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 264 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03437226
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03437226. Randomized; triple masking; primary purpose treatment. Start 2018-03-08 (actual); primary completion 2019-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure
Acronym
LeoDOR
Condition
Heart Failure
Intervention (Drug)
Levosimendan 2.5 MG/ML
Intervention (Drug)
Placebos
Lead sponsor
Dr. Gerhard Pölzl (class: other)
Collaborator
Orion Corporation, Orion Pharma (class: industry)

Record details

Record id
cardio:ct-nct03437226
Content hash
082c94a8ee1a13763f3d296e83939798b007679fa5699d80b426c7f6f4ca9154